The role of current biomarkers in the management of lysosomal storage disorders

Clinical Therapeutics

Volumn 30, Issue SUPPL. 3, 2008, Pages

  Maire, Irène ^a   Guffon, Nathalie ^a   Piraud, Monique ^a   Froissart, Roseline ^a  

^a groupement hospitalier est   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AMINOTRANSFERASE; BIOLOGICAL MARKER; CHITOTRIOSIDASE; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE; FERRITIN; GLOBOTRIAOSYLCERAMIDE; GLYCOSAMINOGLYCAN; HEMOGLOBIN; LACTATE DEHYDROGENASE; TETRASACCHARIDE;

ARTICLE; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; FOLLOW UP; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; MAROTEAUX LAMY SYNDROME; THROMBOCYTE;

EID: 56049125463     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(08)00366-4     Document Type: Article

References (9)

1. Souillet G., Guffon N., Maire I., et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant 31 (2003) 1105-1117
2. Wraith J.E., Beck M., Lane R., et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: Results of a multinational study of recombinant human alpha-l-iduronidase (laronidase). Pediatrics 120 (2007) e37-e46
3. Auray-Blais C., Cyr D., Ntwari A., et al. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab 93 (2008) 331-340
4. PaschkeE, FaulerG, UrbanW, et al. Isoforms of globotriaosylceramide in urine can be used to identify female Fabry patients. Lecture presented at: 16th ESGLD Workshop-European Study Group of Lysosomal Diseases, September 27-30, 2007, Perugia, Italy.
5. Ohashi T., Sakuma M., Kitagawa T., et al. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol Genet Metab 92 (2007) 271-273
6. An Y., Young S.P., Kishnani P.S., et al. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 85 (2005) 247-254
7. van den Hout H.M., Hop W., van Diggelen O.P., et al. The natural course of infantile Pompe's disease: 20 Original cases compared with 133 cases from the literature. Pediatrics 112 (2003) 332-340
8. Aerts J.M., and Hollak C.E. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol 10 (1997) 691-709
9. Deegan P.B., Moran M.T., McFarlane I., et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 35 (2005) 259-267